Clinical Trials
PrimeC led to significant slowing in rate of decline in ALS at 12 months
NeuroSense Therapeutics Ltd. has reported positive results from the 12-month data analysis of a phase 2b study evaluating a novel extended-release oral formulation combination therapy in patients with amyotrophic lateral sclerosis.
Ohio State names new medical oncology director
Christian Rolfo, MD, PhD, MBA, will be the director of the division of medical oncology at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, as of Aug. 15.
Monoclonal antibody for FSHD improves muscle strength with no serious adverse events
Avidity Biosciences Inc. has announced positive data from the phase 1/2 FORTITUDE clinical trial of a proprietary monoclonal antibody that binds to the transferrin receptor 1 conjugated with a siRNA targeting DUX4 mRNA.
Results positive in study of antisense oligonucleotide for Huntington’s disease
Wave Life Sciences has announced positive results from its phase 1b/2a clinical trial of WVE-003, a potential disease-modifying therapeutic for Huntington’s disease.
‘Broader and more inclusive design’ needed for novel cancer trials
Individuals with therapy-refractory cancer who received waivers to participate in a clinical trial for off-label targeted therapies achieved similar clinical benefits as those who took part in the study without an exception.
Cancer Clinical Trials with David Cosgrove, MD
In this episode, host Shikha Jain, MD, speaks with David Cosgrove, MD, about implementing real-world utilization of clinical trials, the importance of diversity in clinical trials and more.
European Commission authorizes subcutaneous Ocrevus for multiple sclerosis
The European Commission has authorized a subcutaneous injection of Ocrevus to treat relapsing multiple sclerosis as well as primary progressive MS, according to the manufacturer.
FDA approves Vyvgart for chronic inflammatory demyelinating polyneuropathy
The FDA has approved Vyvgart Hytrulo in a once-weekly, 30- to 90-second subcutaneous injection to treat adults with chronic inflammatory demyelinating polyneuropathy, according to the manufacturer.
Novel, oral therapeutic for migraine well-tolerated in healthy adults
SAN DIEGO — A novel, oral therapeutic for treatment of migraine was safe and well-tolerated in single ascending doses in a cohort of healthy adults, according to a speaker at the American Headache Society Annual Scientific Meeting.
American Cancer Society launches study focused on cancer risk, outcomes among Black women
The American Cancer Society has launched VOICES of Black Women, a large long-term population study of cancer risk and outcomes among Black women in the United States.